United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer's dividend yield and other value metrics imply good upside for PFE stock. PFE stock is still at least 22% undervalued based on its dividend yield and other valuation metrics.

Dividend Bumps and Buybacks Give Pfizer Stock 20% Upside

Myovant Sciences

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and women's cancer in a deal worth up to $4.2 billion in upfront and potential milestone payments. Myovant will receive an upfront payment of $650 million to develop relugolix, a once-daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women's health in the U.S. and Canada.

Myovant shares soar 16% premarket on news of Pfizer cancer drug deal worth up to $4.2 billion

Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billionORGOVYX(relugolix) is the first approved therapy in the Sumitovant Biopharma family of companies Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billionORGOVYX(relugolix) is the first approved therapy in the Sumitovant Biopharma family of companies

Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

BioNTech SE

With its solid dividend yield and reasonable valuation, there's more to like about PFE stock than just Pfizer's pandemic catalyst. The post As Vaccine Excitement Fades, Buy the Pullback in Pfizer appeared first on InvestorPlace.

As Vaccine Excitement Fades, Buy the Pullback in Pfizer

BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women's health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

Moderna

Cost and logistics will determine the ultimate winner.

Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

Johnson & Johnson

Novavax

3 COVID Vaccine Stocks Smart Investors Are Buying for 2021

What's Behind the Vaccine Feud Between Pfizer and the Feds?

The drugmaker has another experimental vaccine that should generate billions of dollars in sales annually.

Pfizer's Pipeline Candidate That Could Be a Bigger Winner Than Its COVID Vaccine

Intel

J. M. Smucker

Intel is going to be the dominant player in the industry, as many other industries and companies in and outside of technology rely on its chips.

3 Undervalued Dividend Stocks For Christmas: Lanny's Christmas List

Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.

American Airlines

American Airlines and Pfizer should both perform far better than expected in 2021.

2 Must-Own Stocks in 2021

Both biotech companies' vaccines have received approval for emergency use in the U.S. -- but which is a better coronavirus stock?

Better Coronavirus Stock: Moderna or Pfizer?

PayPal

Shopify

Investing doesn't have to be complicated. These three stocks are premium buys for the new year and beyond.

3 Red-Hot Stocks to Buy With Just $1,000

Amgen

Atmos Energy

Bristol-Myers

Cisco Systems

General Dynamics

Lockheed Martin

Merck

Pinnacle West Capital

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of dividend growth stocks in Dividend Radar and present the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For December 2020

Coronavirus vaccine stocks yo-yoed Wednesday as Pfizer won a deal for 100 million more doses in the U.S. and Moderna snagged authorization in Canada for people ages 18 and older. The post Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada appeared first on Investor's Business Daily.

Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada

The government still holds an option to get as many as 400 million more.

Pfizer and BioNTech to Supply Feds With 100 Million Additional Doses of Coronavirus Vaccine

Pfizer Inc. (NYSE: PFE) said on Wednesday that it struck a £1.48 billion deal with the U.S. government under which it will now deliver an additional 100 million doses of its COVID-19 vaccine by the end of July. The ongoing pandemic has so far infected more than 18 million people in the United States and caused over 332 thousand deaths.

Pfizer to deliver 100 million additional doses of its COVID-19 vaccine to the U.S. government

Pfizer has received its share of "no respect" treatment in 2020, but investors should be able to use that to their advantage going forward The post Why Pfizer Stock Deserves a Spot In Your Portfolio appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

Why Pfizer Stock Deserves a Spot In Your Portfolio

Edison

Lam Research

Marsh & McLennan

Primoris Services

Snap-on

Markets rose slightly despite President Donald Trump slamming the stimulus package in a late night video. For investors looking to make the most of this market, our deep learning algorithms have crunched the data to give you a set of Top Buys.

Top Stocks To Buy Today As Markets Trade Higher Despite Stimulus Criticism

The shares of Pfizer Inc. (NYSE:PFE) are up 1.9% at $37.48 at last check, after the pharmaceutical company announced a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion.

Pfizer Stock Surges After Vaccine Deal with U.S. Government

Here's my investor math: Huge medical breakthrough, plus huge PR and reputation breakthrough, plus insatiable demand for new product equals (or should equal) ... something.

Pfizer Stock Just Can't Seem to Find a Cure for Investor Apathy

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

Pfizer to Supply an Additional 100 Million Doses of Covid-19 Vaccine to U.S.

The Covid-19 vaccine isn't a game-changer for Pfizer's valuation. That said, PFE stock was already cheap, and remains a strong buy.

Pfizer Stock Was a Long-Term Place Before Covid and Will Stay One After

Pfizer Inc. and BioNTech SE announced Wednesday a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. That brings the total doses for the U.S. to 200 million.

News for Pfizer Stock (PFE)